Last reviewed · How we verify
Visualization of the ureteral orifices — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Bludigo | Indigo carmine | Provepharm Sas | indigo carmine | 2022-01-01 | ||
| Indigo | INDIGO | Provepharm Sas |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Provepharm Sas · 2 drugs in Visualization of the ureteral orifices
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Visualization of the ureteral orifices:
- Visualization of the ureteral orifices treatment updates — RSS
- Visualization of the ureteral orifices treatment updates — Atom
- Visualization of the ureteral orifices treatment updates — JSON
Cite this brief
Drug Landscape (2026). Visualization of the ureteral orifices — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/visualization-of-the-ureteral-orifices. Accessed 2026-06-10.
Related
- Visualization of the ureteral orifices full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing